Osia® Implant

The Osia System features a powerful implant that sits entirely under the skin. The active implant includes the Piezo Power™ transducer, which generates sound vibrations.

What you'll find on this page

  • How the Cochlear™ Osia® OSI300 Implant is different compared to traditional bone conduction systems.
  • The benefits of Piezo Power™ technology.
  • MRI compatibility.

A hearing implant reimagined

As a part of the Osia System, the OSI300 Implant allows sound to bypass blocked or impaired parts of the natural hearing pathway. The implant is placed fully under the skin, where it's attached to the BI300 Implant. The Piezo Power transducer in the OSI300 Implant creates sound vibrations that are sent through the bone directly to your inner ear.

D1988589-V1_Osia Recip Testimonial Photos_Gabriela_2022_06.jpg

Piezo Power™ technology

The Osia System uses a special Piezo Power transducer that expands and contracts to create powerful vibrations.

One of the many advantages of the Piezo Power transducer is its ability to vibrate at high frequencies.1 This means that in the most difficult listening situations, like a noisy restaurant or a busy classroom, you will hear those sounds that bring clarity to speech understanding.

Testing shows that Piezo Power technology provides powerful and consistent output performance over time.2
Osia Implant_OSI300 update image

The power to hear more

The Osia System is indicated for people with conductive or mixed hearing loss up to 55 dB SNHL.* This means it delivers enough power to address a range of hearing loss levels, and it provides capacity should your hearing loss worsen over time.

Osia recipient Adrian and his friend talk as they sit on a porch swing

"I’ve followed Cochlear for quite a few years, and I knew they had a great reputation. So, I was pretty confident."

- Adrian, Osia System recipient

Designed to implant, made to last

The Piezo Power transducer has a completely different design than traditional bone conduction transducers. The Osia System has demonstrated 99.92% reliability since its release3, and accelerated lifetime testing has demonstrated consistent performance for the Piezo Power transducer over time.4

Hear what you want to hear, not what you don't

The Osia System has been tested in trials across multiple clinics around the world. People who received the new technology showed significant hearing improvement, even in noisy environments.5

Osia System users show a significant improvement in their ability to understand speech in quiet and in noisy environments.⁵

MRI compatible

Many people need an MRI scan at some point in their life. With the OSI300 Implant, you’re able to undergo high-resolution MRI scans at 1.5 and 3 T strength without the need to surgically remove your implant or implant magnet. Testing shows that the performance of the Piezo Power transducer remains consistent after MRI exposure.6

anz-contact-us-device-support.jpg

Contact us

Get in touch with Cochlear

Next

Disclaimer

*Sensorineural hearing loss

Please seek advice from your health professional about treatments for hearing loss. Outcomes may vary, and your health professional will advise you about the factors which could affect your outcome. Always follow the directions for use. Not all products are available in all countries. Please contact your local Cochlear representative for product information.

For a full list of Cochlear’s trademarks, please visit our Terms of Use page.

Views expressed are those of the individual. Consult your health professional to determine if you are a candidate for Cochlear technology. Any testimonial featured is not intended for a New Zealand audience.

In Australia, Cochlear™ Nucleus® implant systems are intended for the treatment of moderately severe to profound hearing loss.

In Australia, Baha® bone conduction implant systems are intended for the treatment of moderate to profound hearing loss.

In Australia, the Cochlear™ Osia® System is indicated for patients with conductive, mixed hearing loss and single-sided sensorineural deafness (SSD) aged 10 years and above with up to 55 decibels sensorineural hearing loss. Patients should have sufficient bone quality and quantity to support successful implant placement. Surgery is required to use this product. Any surgical procedure carries risk.

For Cochlear™ Nucleus®, Osia® and Baha® systems: This product is not available for purchase by the general public. For information on funding and reimbursement please contact your health care professional.

Any testimonial featured on this website is intended for an Australian audience only.

References

  1. Cochlear Limited. Osia System R5 Datasheet. Cochlear Limited, Australia. 2023; D1991788
  2. Dotevall M. Osia OSI200 Implant Technical Brief. Cochlear Limited, Sweden. 2020; D1602089.
  3. Cochlear Limited. Osia Reliability Report. Cochlear Limited, Sweden. 2023; D1841762.
  4. Cochlear Limited. OSI200 Implant Accelerated Life Test Report. Cochlear Limited, Australia. 2019; D1439967.
  5. Briggs R et al. Clinical Performance, Safety and Patient Reported Outcomes of an Active Osseointegrated Steady-State Implant System. Otol. Neurotol. 2022 Aug;43(7):827-834.
  6. Cochlear Limited. OSI200 Implant MRI Safety Verification Report. Cochlear Limited, Australia. 2019; D1439962.